Condition
Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07319767Completed
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
NCT06937567Early Phase 1Recruiting
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
NCT05403554Phase 1Recruiting
A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
NCT01526135Phase 3CompletedPrimary
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic Adenocarcinoma
Showing all 4 trials